Molnupiravir Capsules 200 mg

Composition

Molnupiravir 200mg Capsule

Highlights

1. Reduces the risk of hospitalization in COVID-19 patients
2. Convenient Oral Dosage
3. Having a profound impact in controlling the pandemic
4. A safe, affordable, and effective antiviral drug

Description

Molnucap (Molnupiravir) belongs to the class of antivirals termed as Mutagenic Ribonucleosides. It prevents the replication and transcription of the viral genomes by introducing errors and changes in viral genetic material.

Dosage and Administration

Molnucap (Molnupiravir) can be taken with or without food.

Adults

The recommended dosage of Molnucap (Molnupiravir) is 800mg, (four 200mg capsules) every 8 hours for 5 days.

The safety and efficacy of Molnucap (Molnupiravir), if taken more than 5 days, have not been established.

More Information

Elderly: No dose adjustment is required.

Renal Impairment: No dose adjustment is required.

Hepatic Impairment: No dose adjustment is required.

Pediatric Population: No data is available for the administration of Molnupiravir in patients below 18 years of age.

Pregnancy: Molnupiravir is not recommended during pregnancy. The women of childbearing potential should use effective contraception during the treatment and for 4 days after the last dose of Molnupiravir.

Contraindications:

Hypersensitivity to the active substance

Storage

Store at room temperature (up to 30°C)